<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:27:44.867Z"
        cq:lastModifiedBy="reference-adjustment-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="The Menarini Group announces meropenem/vaborbactam European marketing authorization"
        jcr:uuid="32ca3a37-9bf8-4ed7-a776-3a0063d24d8c"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-935">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    jcr:lastModified="{Date}2023-05-23T15:09:53.441Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        jcr:lastModified="{Date}2023-05-23T15:11:01.995Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/de/menarini-group-news"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1684742346871]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2018-12-20T12:02:00.000Z">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2023-06-07T15:16:13.835Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            jcr:lastModified="{Long}1707398392298"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-MENARINI-GROUP-Logo-2017_miniaturaCS.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            jcr:lastModified="{Date}2023-06-07T15:17:27.212Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            jcr:lastModified="{Long}1707398392301"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;p>&lt;strong>&lt;span style=&quot;color: red;&quot;>&lt;br />&#xa;&lt;/span>&lt;/strong>&lt;/p>&#xa;&lt;p style=&quot;text-align: center;&quot;>&lt;strong>&lt;span style=&quot;color: red;&quot;>&amp;nbsp;&lt;img alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/MENARINI-GROUP-Logo-2017_300.jpg&quot; />&lt;/span>&lt;/strong>&lt;/p>&#xa;&lt;ul>&#xa;    &lt;li style=&quot;text-align: left;&quot;>&lt;strong style=&quot;text-align: justify;&quot;>&lt;span style=&quot;color: windowtext;&quot;>Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections.&lt;/span>&lt;/strong>&lt;/li>&#xa;&lt;/ul>&#xa;&lt;ul>&#xa;    &lt;li style=&quot;margin-left: 0cm; text-align: left;&quot;>&lt;strong>&lt;span style=&quot;color: windowtext;&quot;>The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in Europe.&lt;/span>&lt;/strong>&lt;/li>&#xa;&lt;/ul>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>The Menarini Group has recently reached an agreement with Melinta Therapeutics to commercialize meropenem/vaborbactam in Europe, Asia-Pacific and CIS.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>As highlighted by the Group&amp;rsquo;s General Manager, Pio Mei, &amp;ldquo;The meropenem/vaborbactam European approval is the first great achievement coming from our partnership with Melinta. It confirms Menarini&amp;rsquo;s commitment in the Infectious Disease Area and its involvement in the fight against the antimicrobial resistance threat, a highly unmet need.&amp;rdquo;&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>Meropenem/vaborbactam was initially approved by the FDA for complicated urinary tract infections, including pyelonephritis, in adult patients on the basis of the pivotal &lt;/span>&lt;span>&lt;a href=&quot;https://jamanetwork.com/journals/jama/fullarticle/2673552&quot; target=&quot;_blank&quot;>TANGO I&lt;/a> &lt;/span>&lt;span style=&quot;color: windowtext;&quot;>trial.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>The European approval relied also on the results of the &lt;/span>&lt;span>&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pubmed/30270406&quot; target=&quot;_blank&quot;>TANGO II&lt;/a> &lt;/span>&lt;span style=&quot;color: windowtext;&quot;>trial, the largest trial conducted so far in patients with Carbapenem-Resistant Enterobacteriaceae (CRE) infections. According to the trial&amp;rsquo;s results, the range of clinical indications for meropenem/vaborbactam has been expanded by adding to cUTI (including pyelonephritis) also hospital-acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infections and bacteremia associated with these previous infections.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>Vaborbactam is a potent first-in-class inhibitor of class A (including the KPC, Klebsiella pneumoniae carbapenemase) and class C beta-lactamases, and it protects meropenem from degradation by serine carbapenemases, restoring its activity against carbapenem-resistant strains.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>In &lt;/span>&lt;span>&lt;a href=&quot;https://www.ncbi.nlm.nih.gov/pubmed/30270406&quot; target=&quot;_blank&quot;>TANGO II&lt;/a>&lt;/span>&lt;span style=&quot;color: windowtext;&quot;>, meropenem/vaborbactam as intravenous monotherapy, compared with the &amp;ldquo;best available treatment,&amp;rdquo; was associated with increased clinical cure, reduced mortality, and lower treatment-related AEs (e.g. nephrotoxicity). The increased cure rate was statistically significant also in immunocompromised patients, a group usually excluded from clinical trials.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>The spread of carbapenem resistance in Gram negative bacteria represents a serious and growing threat worldwide as identified by the WHO and CDC.&amp;nbsp; CRE infections, because of limited therapeutic options, are associated with high rates of mortality as well as increased length of hospital stay and costs. According to&lt;/span>&lt;span> &lt;a href=&quot;https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30605-4/fulltext&quot; target=&quot;_blank&quot;>the most recent data&lt;/a>&lt;/span>&lt;span style=&quot;color: windowtext;&quot;> from the European Antimicrobial Resistance Surveillance Network (EARS-Net), the prevalence of invasive CRE isolates reaches worrisome levels particularly in some European countries. Romania, Italy and Greece show a rate of 31%, 34% and 67%, respectively, for invasive Klebsiella pneumoniae isolates (from blood and cerebrospinal fluid) with resistance to carbapenems.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>&amp;nbsp;&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>In this context, meropenem/vaborbactam appears to be a potential game changer in the fight against difficult-to-treat Gram negative infections, satisfying an important medical issue linked to antibiotic-resistant Enterobacteriaceae.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;strong>&lt;span style=&quot;color: windowtext;&quot;>&amp;nbsp;&lt;/span>&lt;/strong>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;strong>&lt;span style=&quot;color: windowtext;&quot;>About the Menarini Group&lt;/span>&lt;/strong>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span style=&quot;color: windowtext;&quot;>The Menarini Group is an Italian pharmaceutical company with a turnover of 3.6 billion Euro and more than 17,000 employees. With 16 manufacturing sites and 7 R&amp;amp;D centers, Menarini has a capillary presence in 136 countries.&lt;/span>&lt;/p>&#xa;&lt;p style=&quot;text-align: left;&quot;>&lt;span>&lt;a href=&quot;http://www.menarini.com/&quot;>www.menarini.com&lt;/a>&lt;/span>&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-MENARINI-GROUP-Logo-2017_miniaturaCS.jpg"/>
    </jcr:content>
</jcr:root>
